Healx Logo

Company

We’re Healx

18 nationalities in 10 locations worldwide, all driven by the shared purpose of breaking new grounds in the discovery of new treatments for rare diseases

A truly patient-inspired AI company – our story

Healx went from being an idea to a reality when our co-founders, Dr Tim Guilliams and Dr David Brown, met a man named Nick Sireau.

More than a decade earlier, Nick had set up a patient group to help save his sons from an extremely rare genetic disorder. He worked tirelessly, but the drug discovery process was slow and went into the millions of dollars, and this is a problem many patient groups still face today. And the truth is that most patient groups don’t find success. Nick was lucky that he did, and it was in the unlikeliest of places: a drug that had originally been developed as a weed killer.

Tim and Dave had long been advocating the benefits of drug repurposing, in combination with the power and speed of AI. Nick became their inspiration – he was the living story of the therapeutic need their abilities could meet.

This encounter took place in 2014 and we’ve been growing ever since. Today, we’re a 30+ strong, world-class team of drug discoverers, AI engineers, and bioinformaticians, all working together to accelerate the discovery of new treatments for rare diseases.

Vector

Leadership team

Dr Tim Guilliams

Dr Tim Guilliams

Co-Founder and CEO

Tim is a tech entrepreneur from the Cambridge Cluster (UK). He is passionate about using big data and artificial intelligence to accelerate treatments for rare diseases. He is the Co-Founder and Chief Executive of Healx Ltd, a tech company focused on treatment predictions for rare diseases. Healx was selected in the global 'Disrupt 100' list 2017, covered in the Harvard Business Review, finalist of Pitch@Palace and awarded 'Cambridge Startup of Year' 2016 and 'Cambridge Life Science Business of the Year' 2015.

Passionate about patient impact, Tim is also the Co-Founder and Trustee of the Cambridge Rare Disease Network (CRDN). Prior to Healx and CRDN, he obtained his PhD at the University of Cambridge in the field of Biophysics and Neuroscience, developing Nanobody technology for Parkinson's disease. Before moving to Cambridge UK, Tim obtained an MEng in Bio- and Chemical-Engineering from the University of Brussels.

Read bio
Dr Neil Thompson

Dr Neil Thompson

Chief Scientific Officer

Over the last 30+ years, Neil’s career has seen him progress more than 10 drugs to patients and he’s led a number of drug discovery projects in areas of cardiovascular, neurology, inflammation and oncology among others.

For 15 years, Neil was Senior Vice President of Biology at Astex Pharmaceuticals, helping the company establish itself at the forefront of drug discovery by leading the biology and pre-clinical teams to deliver two new cancer drugs (Kisqali; ribociclib and Balversa; erdafitinib in partnership with Novartis and Janssen respectively) to market. Before that, he was Director of the Immunology Platform at GlaxoSmithKline (GSK).

Neil is also Deputy Chair of the UK MRC DPFS panel and Chair of the MRC CLD/ADI committee, has authored more than 40 publications and patents and sits on the advisory boards of several scientific institutions in the UK.

Neil received his doctorate in Biochemistry from King’s College London.

Read bio
Dr Kate Hilyard

Dr Kate Hilyard

Chief Operating Officer

Kate has always been driven to make a difference in patients’ lives, from her early academic research at Oxford and Harvard Universities, to leading drug discovery teams and organisations in the industry. Prior to joining Healx, Kate was Corporate VP at Charles River Discovery, leading a team of over 400 drug discovery scientists in three countries. The client-base was worldwide, and under her leadership, the organization delivered on average 3-4 preclinical drug candidates per year for its partners. Her 25+ years of industry experience includes senior leadership positions in Cambridge Antibody Technology as Director of Discovery Biology and Roche as Head of Inflammatory Diseases.

Kate’s leadership, strong scientific, financial and commercial acumen culminate in a reputation for quality and delivery while ensuring a sustainable business and generating value for shareholders.

Read bio
Dr Ian Roberts

Dr Ian Roberts

Chief Technology Officer

As a senior investigator at Cambridge’s MRC Cancer Cell Unit, Ian led the development of molecular cytogenetic and genomics approaches for the discovery of disease genes in small round blue cell tumours and cervical carcinoma. During this time Ian developed algorithms for copy number imbalance analysis and integration with expression data using array-based techniques.

Following a move to industry, as Head of Informatics at Population Genetics Technologies Ltd, Ian led the development of next-generation DNA sequencing (NGS) variant discovery pipelines. Ian continued to develop NGS-based variant discovery workflows as Senior Bioinformatician at 14M Genomics before joining Healx in 2016.

Read bio
Dr Bruce E. Bloom

Dr Bruce E. Bloom

Chief Collaboration Officer

Dr Bruce Bloom is the founder and former CEO of Cures Within Reach, a leading global non-profit saving lives by unleashing the untapped potential of human approved drugs, devices, diagnostics and nutraceuticals, testing new uses for them to quickly deliver safe and affordable treatments and cures for diseases that have no currently effective therapy.

Bruce envisioned and created CureAccelerator®, the first online repurposing research collaboration platform, to bring together clinicians, researchers, funders, and industry to create and conduct proof of concept repurposing clinical trials. Dr Bloom is an Ashoka Social Entrepreneur Fellow, the Patient Advisory Board Chair for the Institute for Translational Medicine, board member of the Drug Discovery Center and Chair of the Cancer Center Advancement Advisory Boards at the University of Illinois Chicago, member of the Vanderbilt Institute for Clinical and Translational Research External Advisory Board, and is on the Science Advisory Boards of Rediscovery Life Sciences, the Dr. Ralph and Marian Falk Medical Research Trust Awards Programs, the Findacure Fundamental Disease Charity, the Rare Disease Research Hub of the Westchester Biotech Project, OneThree Biotech, and Cures Within Reach for Cancer, and is a member of the editorial board of ASSAY and Drug Development Technologies.

Read bio
Dr Michale Bouskila-Chubb

Dr Michale Bouskila-Chubb

Head of Business Development

Michale joined Healx in 2017 and brings over 10 years of business experience in life sciences. After a career in research in both academia and industry in the field of physiology and human metabolism, Michale completed an MBA specialising in Healthcare. From there, she went on to hold various commercial positions in management consultancy, technology transfer and pharmaceutical business development. Michale has a strong background in commercial strategy, IP exploitation and contract negotiations. She recently received the PLG (Pharmaceutical Licensing Group) Business Development Award for Best Newcomer of the Year (2018) and was recognised in the 50 Movers and Shakers in BioBusiness report (2019).

Michale holds a Pharmacy doctorate and a Toxicology Master’s degree from Paris V University, a PhD from the University of Dundee and an MBA from the Open University Business School.

Read bio
Dr Andrea Pierleoni

Dr Andrea Pierleoni

Head of AI

Andrea has 15 years experience in applying machine learning techniques on biomedical big data to deliver novel solutions for drug discovery both in academia and biotech industry. Before joining Healx, he played a key role in the development of the Open Targets Platform, a pre-competitive target discovery effort between several large Pharma companies and leading academic institutions.

Andrea has a degree in Pharmaceutical Biotechnology and a PhD in Computational Biology from the University of Bologna.

Read bio
Dr Michael Motskin

Dr Michael Motskin

Head of Digital Strategy

Michael holds a rare background in both science and digital strategy, which allows him to make complex scientific concepts accessible to end users. Before joining Healx, and after completing a postdoc at Imperial College London, he worked as a campaign manager, project manager and scientific consultant for a number of digital agencies. But Michael is probably best known as the co-founder and Managing Director of Pint of Science, a science festival held in more than 400 cities across 24 countries, making it the largest science festival in the world.

Michael holds a PhD in nanobiology from the University of Cambridge.

Read bio
Dr Julie Charlton

Dr Julie Charlton

Clinical Director

Julie has over 20 years experience in drug development, spanning discovery research to late-phase clinical, in academic, biotech and pharma settings. Before joining Healx, Julie lead global clinical development programs in AstraZeneca’s early phase oncology R&D unit. Julie also has a background in mentoring startup companies and has set up several successful social enterprise businesses, including local food and early years education initiatives. She is a qualified teacher and received her doctorate in Physiology from King’s College London.

Read bio
David Campbell

David Campbell

Finance Director

David is a Fellow of the Association of Chartered Certified Accountants and has an MBA from Manchester Business School. He has over 23 years’ experience in the biotechnology and pharmaceutical industry, having held senior positions with Cambridge Antibody Technology, Boehringer Ingelheim, Alizyme and Genzyme.

In May 2010, David joined The Automation Partnership (TAP) as Finance Director and played a key role in the trade sale of this business to Sartorius Stedim Biotech in December 2013. David then led the financial integration of TAP into Sartorius, before taking on a broader role as Finance Director for the Sartorius North European region.

David has extensive experience of corporate finance, acquisitions, international licensing transactions, corporate restructuring, business integration, corporate communications and investor relations.

Read bio

Board of directors

Dr Tim Guilliams

Dr Tim Guilliams

Co-Founder and CEO

Tim is a tech entrepreneur from the Cambridge Cluster (UK). He is passionate about using big data and artificial intelligence to accelerate treatments for rare diseases. He is the Co-Founder and Chief Executive of Healx Ltd, a tech company focused on treatment predictions for rare diseases. Healx was selected in the global 'Disrupt 100' list 2017, covered in the Harvard Business Review, finalist of Pitch@Palace and awarded 'Cambridge Startup of Year' 2016 and 'Cambridge Life Science Business of the Year' 2015.

Passionate about patient impact, Tim is also the Co-Founder and Trustee of the Cambridge Rare Disease Network (CRDN). Prior to Healx and CRDN, he obtained his PhD at the University of Cambridge in the field of Biophysics and Neuroscience, developing Nanobody technology for Parkinson's disease. Before moving to Cambridge UK, Tim obtained an MEng in Bio- and Chemical-Engineering from the University of Brussels.

Read bio
Dr David Brown

Dr David Brown

Co-Founder and Chairman of the Board

Dr David Brown has 40 years experience in the pharmaceutical / biotechnology industry both in research and in senior executive roles. He served with 4 of the top 10 pharmaceutical companies: Zeneca, Pfizer, GlaxoWellcome, and Hoffman La-Roche. Whilst at Pfizer he was named co-inventor on the patent for Viagra, and for 8 years he led the team that invented and developed Viagra through to proof of clinical efficacy in male impotence. The drug is also marketed for treatment of pulmonary hypertension under the trade name Revatio. He also had a pivotal role in the discovery of Relpax, a treatment for migraine. Together these drugs have achieved sales of over $40 billion. While at Roche in Switzerland, he was a Director of the company and, as Global Head of Drug Discovery, he had responsibility for productivity of over 2000 scientists at Roche’s five research sites in the USA, Europe and Asia.

David subsequently co-founded antibody company Crescendo Biologics and serves on the boards of Healx Ltd (Chair), ProFactor Pharma Ltd (Chair) and Babraham Institute Enterprise Ltd (Chair). He is a Trustee (Director) of Friends of Manjushree Vidyapith School and Orphanage (FMVSO), a charity he co-founded in 2005 to help destitute orphans in South Tibet.

Read bio
Irina Haivas

Irina Haivas

Board member

Irina Haivas is a Principal at Atomico. She is passionate about machine intelligence-enabled businesses, next generation biology, robotics and automation, and other frontier technologies. She also focuses on companies in healthcare. Before joining Atomico, Irina was a growth and PE investor at healthcare-focused fund GHO Capital, and a strategy consultant at Bain & Co. where she worked with over 30 companies across Europe and the U.S. Irina trained as a doctor, and was a surgical fellow at Harvard Medical School before completing an MSc (Dist) in International Health Policy at the London School of Economics.

Read bio
Suranga Chandratillake

Suranga Chandratillake

Board member

Suranga joined Balderton as a General Partner in 2014. He was previously an entrepreneur and engineer. Suranga founded blinkx, the intelligent search engine for video and audio content in Cambridge in 2004. He then led the company for eight years as CEO through its journey of moving to San Francisco, building a profitable business and going public in London where it achieved a peak market capitalisation in excess of $1Bn. Before founding blinkx, Suranga was an early employee at Autonomy Corporation - joining as an engineer in the Cambridge R&D team and ultimately serving as the company's US CTO in San Francisco.

Suranga has a MA in Computer Science from the University of Cambridge. He holds patents in the area of video discovery and online video advertising, was elected a Fellow of the Royal Academy of Engineering in 2012 and was chosen as one of the World Economic Forum's Young Global Leaders in 2009. In 2017, Suranga joined the UK Government's Council for Science and Technology. Suranga was granted an OBE for services to technology and engineering in the 2018 UK New Year's Honours.

Read bio
Jonathan Milner

Jonathan Milner

Board member

Jonathan, Co-Founder and current Deputy Chairman of Abcam plc, is an entrepreneur and investor who is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 40 companies and has assisted three technology companies to IPO on the London AIM Stock Exchange.

Jonathan gained his doctorate in Molecular Genetics at Leicester University after graduating in Applied Biology at Bath. From 1992-95, he was a post-doctoral researcher at Bath, following which he worked at the University of Cambridge in the lab of Professor Tony Kouzarides researching the molecular basis of breast cancer. He identified the market opportunity for supplying high-quality antibodies to support protein interaction studies, and in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides.

Jonathan is also a non-executive director of Healx, Shift Bioscience and Syndicate Room. He is also Chairman of Axol Bioscience, Cambridge Allergy, PhoreMost.

In 2015 Jonathan, with Professor Tony Kouzarides, co-founded the Milner Therapeutics Institute at the University of Cambridge. Also in 2015 he co-founded, with Professor Laurence Hurst, the Milner Centre for Evolutionary Studies at the University of Bath.

Read bio
Shaun Grady

Shaun Grady

Board member

Shaun Grady has responsibility for Global Business Development at AstraZeneca, leading the company’s transaction execution, due diligence and Alliance and Integration Management function including externalisation, licensing and partnering, M&A, and divestments.Shaun was appointed to his current role in 2013 with the creation of the Global Product and Portfolio Strategy (GPPS) unit. Prior to this, he was Vice President, Strategic Partnering & Business Development (2010-13) and Vice President, Corporate Business Development (2006-10).

Shaun originally joined ICI as an attorney and held positions in the pharmaceuticals, petrochemicals, and legal departments. Following the demerger from ICI, he was appointed Assistant General Counsel, Corporate for Zeneca.Shaun worked on the merger of Astra and Zeneca, the merger of Zeneca Agrochemicals with Novartis Agribusiness to form Syngenta, and the creation of Avecia. Shaun also worked on the acquisition of Cambridge Antibody Technology (CAT), led the acquisition of Amylin, and subsequent buy-out of Bristol-Myers’ Squibb’s interest in the AZ-BMS Diabetes Alliance. In addition, he has spent time in the US business managing the legal function and also completed a two year secondment to HR, leading a global People Strategy change project.

Shaun is an Honorary Fellow in Entrepreneurship at Cambridge Judge Business School and is a member of the Board of Cambridge United Football Club and Cambridge Arts Theatre.

Based in Cambridge, Shaun enjoys rugby and football, and occasionally turns his hand to sports writing.

Read bio

Advisory board

Dr Andreas Bender

Dr Andreas Bender

Reader for Molecular Informatics, Cambridge University
Elia Stupka

Elia Stupka

SVP and General Manager - Life Sciences Business at Health Catalyst
Dr Ronjon Nag

Dr Ronjon Nag

Inventor and entrepreneur specialising in mobile technology
Dr Nick Sireau

Dr Nick Sireau

Chairman of AKU and founder of Find a Cure
Ms Hanadi Jabado

Ms Hanadi Jabado

Director of Enterprise at Cambridge Judge Business School, and Director of Pitch@Palace
Dr Darrin Disley OBE

Dr Darrin Disley OBE

CEO and Investor, Mogrify, former CEO of Horizon Discovery
Professor Tim Cox

Professor Tim Cox

Physician, Addenbrooke’s Hospital Director MB/PhD Programme
Dr Mike Tranfaglia

Dr Mike Tranfaglia

Medical Director and Chief Scientific Officer, FRAXA Research Foundation

Careers

Let’s be clear: we’re big thinkers and we need the best and brightest.

Recent news

Our latest press releases and news